Effects of simvastatin on carotenoid status in plasma

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 1, 2012, Pages 66-71

  Ryden M ^a   Leanderson, P ^a   Kastbom, K O ^a   Jonasson, L ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Carotenoid; Inflammation; Lipid; Lipoprotein; Statin

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CAROTENOID; CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIOXIDANTS; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTENOIDS; CHOLESTEROL; DOUBLE-BLIND METHOD; HUMANS; HYPERCHOLESTEROLEMIA; INTERLEUKIN-6; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 83855165827     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.04.009     Document Type: Article

References (30)

1. Hulthe J., Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002, 22:1162-1167.
2. Meisinger C., Baumert J., Khuseyinova N., Loewel H., Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005, 112:651-657.
3. Karppi J., Nurmi T., Kurl S., Rissanen T.H., Nyyssönen K. Lycopene, lutein and β-carotene as determinants of LDL conjugated dienes in serum. Atherosclerosis 2009, [e-pub ahead of print].
4. Kontush A., Weber W., Beisiegel U. α- and β-carotenes in low density lipoproteins are the preferred target for nitric oxide-induced oxidation. Atherosclerosis 2000, 148:87-93.
5. Britton G. Structure and properties of carotenoids in relation to function. FASEB J 1995, 9:1551-1558.
6. Rissanen T.H., Voutilainen S., Nyyssönen K., Lakka T., Sivenius J., Salonen R., et al. Low serum lycopene concentrations is associated with an excess incidence of acute coronary events and stroke: the Kuopi ischemic heart disease risk factor study. Br J Nutr 2001, 85:749-754.
7. Buijsse B., Feskens E.J., Kwape L., Kok F.J., Kromhout D. Both alpha- and beta-carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men. J Nutr 2008, 138:344-350.
8. Ito Y., Kurata M., Suzuki K., Hamajima N., Hishida H., Aoki K. Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. J Epidemiol 2006, 16:154-160.
9. Riccioni G., D'Orazio N., Palumbo N., Bucciarelli V., Ilio E., Bazzano L.A., et al. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia Study. Eur J Cardiovasc Prev Rehabil 2009, 16:351-357.
10. Hosawa A., Jacobs D.R., Steffes M.W., Gross M.D., Steffen L.M., Lee D.-H. Circulating carotenoid concentrations and incident hypertension: the coronary artery risk development in young adults (CARDIA) study. J Hypertens 2009, 27:237-242.
11. Dwyer J.H., Navab M., Dwyer K.M., Hassan K., Sun P., Shircore A., et al. Oxygenated carotenoid lutein and progression of early atherosclerosis: the Los Angeles atherosclerosis study. Circulation 2001, 103:2922-2927.
12. Dwyer J.H., Paul-Labrador M.J., Fan J., Shircore A.M., Merz C.N., Dwyer K.M. Progression of carotid intima-media thickness and plasma antioxidants: the Los Angeles Atherosclerosis Study. Arterioscler Thromb Vasc Biol 2004, 24:313-319.
13. Koh W.-P., Yuan J.-M., Wang R., Lee Y.-P., Lee B.-L., Yu M.C., et al. Plasma carotenoids and risk of acute myocardial infarction in the Singapore Chinese Health Study. Nutr Metab Cardiovasc Dis 2010, Epub ahead of print.
14. Chew B.P., Park J.S. Carotenoid action on the immune response. J Nutr 2004, 134:257S-261S.
15. Kritchevsky S.B., Bush A.J., Pahor M., Gross M.D. Serum carotenoids and markers of inflammation in nonsmokers. Am J Epidemiol 2000, 152:1065-1071.
16. Erlinger T.P., Guallar E., Miller E.R., Stolzenberg-Solomon R., Appel L.J. Relationship between systemic markers of inflammation and serum beta-carotene levels. Arch Intern Med 2001, 161:1903-1908.
17. Jonasson L., Wikby A., Olsson A.G. Low serum beta-carotene reflects immune activation in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 2003, 13:120-125.
18. van Herpen-Broekmans W.M., Klöpping-Ketelaars I.A., Bots M.L., Kluft C., Princen H., Hendriks H.F., et al. Serum carotenoids and vitamins in relation to markers of endothelial function and inflammation. Eur J Epidemiol 2004, 19:915-921.
19. Lidebjer C., Leanderson P., Ernerudh J., Jonasson L. Low plasma levels of oxygenated carotenoids in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 2007, 17:448-456.
20. Hosawa A., Jacobs D.R., Steffes M.W., Gross M.D., Steffen L.M., Lee D.-H. Relationships of circulating carotenoid concentrations with several markers of inflammation, oxidative stress, and endothelial dysfunction: the coronanry artery risk development in young adults (CARDIA)/young adult longitudinal trends in antioxidants (YALTA) study. Clin Chem 2007, 53:447-455.
21. Wang L., Gaziano J.M., Norkus E.P., Buring J.E., Sesso H.D. Associations of plasma carotenoids with risk factors and biomarkers related to cardiovascular disease in middle-aged and older women. Am J Clin Nutr 2008, 88:747-754.
22. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment TrialistŚ(CTT) Collaborators.
23. Kwak B.R., Mulhaupt F., Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2003, 2:332-338.
24. Forrester J.S., Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007, 99:732-738.
25. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933-1935.
26. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. for the JUPITER Study group.
27. Cherfan P., Tompa A., Wikby A., Löfgren S., Jonasson L. Effects of simvastatin on human T cells in vitro. Atherosclerosis 2007, 193:186-192.
28. Vasankari T., Ahotupa M., Viikari J., Nuotio I., Strandberg T., Vanhanen H., et al. Effect of 12-month statin therapy on antioxidant potential of LDL and serum antioxidant vitamin concentrations. Ann Med 2004, 36:618-622.
29. Shin M.J., Chung N., Lee J.H., Jang Y., Park E., Jeon K.I., et al. Effects of simvastatin on plasma antioxidant status and vitamins in hypercholesterolemic patients. Int Journal Cardiol 2007, 118:173-177.
30. Gray A., Wilson C., McMillan D.C., Williamson C., óReilly D.S.J., Talwar D. The relationship between the acute changes in the systemic inflammatory response, lipid soluble antioxidant vitamins and lipid peroxidation following elective knee arthroplasty. Clin Nutr 2005, 24:746-750.